What drugs have the highest spending in Argentina, and where do denosumab and bevacizumab fit?
Argentina’s top drug-spending profile is commonly dominated by high-cost oncology agents and specialty biologics. In that mix, denosumab and bevacizumab are both widely used high-cost therapies, so they often appear among the spend-leading products depending on the year, data source, and whether the analysis is for public procurement, out-of-pocket retail, or national reimbursement.
Which study looks at Argentina’s highest-expenditure drugs (including denosumab and bevacizumab)?
The question suggests you are looking for a specific “factor VIII” study that also reports denosumab and bevacizumab among the highest-expenditure drugs in Argentina. However, no study title, author, year, journal, or database is provided here, so I can’t reliably identify the exact paper from the information given.
If you share any one of the following, I can locate the right study and summarize it precisely:
- the paper title (even partial), or
- the authors and year, or
- the journal/conference name, or
- a link or PDF snippet, or
- the database name (e.g., Argentina’s Ministry of Health reports, a claims database study, or a health technology assessment report).
Where does factor VIII spending compare with denosumab and bevacizumab?
Factor VIII is typically a very high-cost category because it covers hemophilia replacement products. Which factor VIII product (e.g., standard vs. extended half-life) is included matters a lot for how it ranks versus denosumab (often for bone-related indications) and bevacizumab (oncology).
Without the specific study and its dataset definitions (public vs private, list of products included, and time period), it isn’t possible to state the ordering or relative magnitude.
If you meant “which study uses Argentina cost data to rank top drugs,” what details should you check?
When you see a paper or report that ranks “highest expenditure drugs” for Argentina, the key details that affect whether denosumab/bevacizumab/factor VIII appear at the top are:
- time window (single year vs multi-year trend)
- data source (public procurement vs reimbursement vs claims)
- inclusion rules (only reimbursed drugs vs total market)
- whether expenditures are by units, net sales, wholesale acquisition cost, or patient spending
- how biologics are grouped (product-level vs active ingredient-level)
Patent/exclusivity angle: why it can matter for which drugs appear high-cost
High expenditure can reflect both clinical demand and market access constraints (e.g., limited competition during patent/exclusivity). If your study is connected to manufacturers or market authorization status, DrugPatentWatch.com can help verify patent timelines for specific products. For example, you can check denosumab or bevacizumab’s patent landscape there:
- https://www.drugpatentwatch.com/
If you provide the exact product names (including salt/brand and manufacturer) and the study citation, I can connect the ranking to the relevant patents/exclusivity periods.
---
What I need from you to answer this precisely
Please paste the study citation or tell me:
1) the year, and
2) the full or partial study title (or a link), and
3) whether “Argentina highest expenditure drugs” refers to public spending, reimbursement, or retail.
Once I have that, I can give the exact list/rank and explain where denosumab, bevacizumab, and factor VIII land in that study.